Physicochemical Properties
| Molecular Formula | C21H24N2O4 |
| Molecular Weight | 368.426265716553 |
| Exact Mass | 368.173 |
| CAS # | 2237054-53-2 |
| PubChem CID | 137319628 |
| Appearance | White to off-white solid powder |
| LogP | 3.8 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 27 |
| Complexity | 430 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O(C)C1C(=C(C=C(C=1)C1C(=CN(C)N=1)C1C=CC(=CC=1)OCC)OC)OC |
| InChi Key | YWYCRTNRTJCKHS-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C21H24N2O4/c1-6-27-16-9-7-14(8-10-16)17-13-23(2)22-20(17)15-11-18(24-3)21(26-5)19(12-15)25-4/h7-13H,6H2,1-5H3 |
| Chemical Name | 4-(4-ethoxyphenyl)-1-methyl-3-(3,4,5-trimethoxyphenyl)pyrazole |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Tubulin inhibitor 1 (compound 7a3) is a tubulin inhibitor that prevents tubulin polymerization [1]. Strong anti-proliferative activity of tubulin inhibitor 1 has been observed against SK-OV-3, MDA-MB-231, HeLa, A549, CT26, and MCF-7 cells; IC50 values are 16.7 ± 3.0, 31.4 ± 0.7, 32.8 ± 2.9, 67.0 ± 0.8, 58.0 ± 2.4, and 35.4 ± 5.6 nM, in that order [1]. In SK-OV-3 cells, tubulin inhibitor 1 (40, 80, and 160 nM, 48 hours) dramatically stopped cell mitosis in the G2/M phase and triggered apoptosis [1]. |
| ln Vivo | Tubulin Inhibitor 1 (50 mg/kg, i.p., three times every two days for 20–25 days) significantly reduced the number of SK-OV-3 cell-bearing Balb/c nude mice while also being well tolerated. of tumor development [1]. |
| Cell Assay |
Apoptosis analysis [1] Cell Types: SK-OV-3 Cell Tested Concentrations: 40, 80 and 160 nM Incubation Duration: 48 hrs (hours) Experimental Results: SK-OV-3 cells induced apoptosis after 48 hrs (hours) of treatment. |
| Animal Protocol |
Animal/Disease Models: Sixweeks old Balb/c nude mice (18-20 g), carrying SK-OV-3 cells [1] Doses: 50 mg/kg Route of Administration: IP, 3 times every two days for 20-25 Experimental Results: The tumor growth of Balb/c nude mice carrying SK-OV-3 cells was Dramatically diminished, but the body weight was not Dramatically diminished. |
| References |
[1]. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3. Eur J Med Chem. 2018 Aug 5;156:162-179. |
Solubility Data
| Solubility (In Vitro) | DMSO : ≥ 125 mg/mL (~339.28 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.65 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (5.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7142 mL | 13.5711 mL | 27.1422 mL | |
| 5 mM | 0.5428 mL | 2.7142 mL | 5.4284 mL | |
| 10 mM | 0.2714 mL | 1.3571 mL | 2.7142 mL |